Zyprexa

Sales of Strattera, Lilly‘s treatment for attention deficit disorder, slipped 8 percent to $168 million, hurt by the recent placement of a prominent warning inside the packaging that it may increase risk of suicidal thoughts among children and adolescents.

Sales of Lilly‘s diabetes products rose 11 percent to $750 million, helped by the introduction of a new drug called Byetta and higher prices for older treatments.

Sales of Alimta, a new treatment for lung cancer, rose 86 percent to $136 million.

Injectable osteoporosis drug Forteo jumped 59 percent to $118 million, while sales of older treatment Evista rose 3 percent to $265 million.

Cialis, the anti-impotence pill sold in p - ), rose 38 percent to $211 million.

S - ) rival Viagra fell in the quarter, hurt by competition from Lilly‘s longer-acting product.

Lilly reaffirmed its 2006 earnings forecast of $3.10 to $3.20 per share, first delivered last month and excluding special items.

It is in line with the average estimate of $3.13 among analysts polled by Reuters Estimates.

The company forecast first-quarter earnings of 73 cents to 75 cents per share, representing growth of 7 percent to 10 percent over the 2005 period.

The forec...

Read more...